IL6 and atherosclerosis: The study results showed that ziltivekimab significantly reduced levels of biomarkers of atherosclerosis-related inflammation and thrombosis, such as hsCRP, compared with placebo, which further demonstrated the important role of IL-6 in atherosclerosis and thrombosis.